[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prebiotics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prebiotics":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,65,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":40,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100648817","prebiotic-inulin-for-late-reproductive-individuals-100648817",false,"NCT07724522","Prebiotic Inulin for Late-Reproductive Individuals","A Placebo Randomized Cross-Over Controlled Trial of Inulin Supplementation to Improve Cardiometabolic, Gut, and Vaginal Microbiome in Perimenopausal Women","PILI","Inclusion Criteria:\n\n* Body mass index: 25 - 40 kg\u002Fm2;\n* Menstrual cycle irregularity (cycle length outside 21 - 35 days or variation \\> 7 days) or\u002Fand ≥ 2 skipped cycles and interval of ≥ 60 days of amenorrhea; with or without hot flashes or\u002Fand night sweats;\n* Weight stable within the last 3 months (body weight fluctuations within the 5% of their habitual body weight);\n* Spending ≥ 6 hours sitting;\n* \\\u003C 150 minutes per week (50 minutes per day, 3 days per week OR 30 minutes per day, 5 days per week) of moderate to vigorous structured physical activity (i.e., planned intentional physical activity, not incidental movement).\n\nExclusion Criteria:\n\n* Recent antibiotic use oral or vaginal (≥ 6months);\n* Diagnosed with any chronic disease (e.g., any gastrointestinal condition like IBD, type 2 diabetes, or cancer);\n* Prescription of hormone replacement therapy, hormonal contraceptives, probiotics, GLP-1 medications, or weight loss medications\n* Smoking;\n* Recent blood donation (within the past 8-12 weeks);\n* Significant weight changes (≥5%) in the last 4 weeks;\n* Use of dietary supplements (unless discontinued 4 weeks prior);\n* Participants taking long-term, stable medications for chronic conditions such as hypertension or hyperlipidemia will not be excluded if their medication regimen has been unchanged for at least 2 years, as these treatments are part of their usual health status. Recent medication changes (within the past 6 months), initiation of new prescriptions, or use of medications known to affect metabolic, vascular, vaginal, hormonal, or gastrointestinal function will result in exclusion.\n* Fructose intolerance.","FEMALE","40 Years","55 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the effects of 2 weeks of inulin supplementation in perimenopausal women with overweight or obesity. The primary questions this study seeks to answer are:\n\n1. Does 2 weeks of inulin supplementation alter the gut and vaginal estrobolome compared with placebo?\n2. Does 2 weeks of inulin supplementation affect cardiovascular health compared with placebo?\n3. Does 2 weeks of inulin supplementation affect skeletal muscle health compared with placebo?\n\nResearchers will compare inulin with a placebo (a similar-looking supplement that does not contain inulin) to determine whether inulin influences gut and vaginal microbial function, cardiovascular health, and skeletal muscle health during the perimenopausal transition.\n\nParticipants will:\n\n* Take either inulin or a placebo for 2 weeks, followed by a 2- to 4-week washout period, and then switch to the other supplement for an additional 2 weeks.\n* Attend 8 study visits over approximately 12 to 16 weeks for assessments and sample collection.\n* Complete weekly phone calls to monitor symptoms, supplement adherence, and dietary intake.\n* Wear a Fitbit device throughout the study to monitor physical activity.",[28,29,30,31,32,33,34,35,36,37,38,39],"Obesity & Overweight","Perimenopausal Women","Prebiotics","Inulin","Muscle, Skeletal","Cardiovascular Diseases (CVD)","Microbiota","Gastrointestinal Microbiome","Dietary Fiber","Women Health","Vascular Health","Insulin Resistance",[41,42,43,44,45,46,47,48,49,50,51,31,38],"Perimenopause","Nutrition","Menopause transition","Overweight","Obesity","Cardiometabolic Health","Vascular function","Randomized Controlled Trial","Gut microbiome","Vaginal microbiome","Supplements","RECRUITING","2026-08-07",{"date":55,"type":56},"2026-08-11","ACTUAL",{"date":58,"type":56},"2026-08-01",{"date":60,"type":22},"2028-02",{"name":62,"class":63},"George Washington University","OTHER",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":72,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":91,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":64},"100592604","dietary-supplements-in-patients-with-coronary-artery-bypass-grafting-for-improving-the-quality-of-healthcare-delivery-100592604","NCT06995586","Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","Inclusion Criteria:\n\n* The subjects will be people 40-80 years old, with coronary artery disease, and mental clarity who will undergo Coronary Aortic Bypass (CABG) in our clinic (Public Cardiothoracic Surgery clinic in Nicosia General Hospital) and will be randomized into 2 groups (intervention group and control group).\n* Signed consent form\n* Ability to adhere to the protocol\n\nExclusion Criteria:\n\n* Any psychiatric, neurological or motor disorder.\n* Hypersensitivity to the components of the supplement.\n* Combined Cardiac Surgery other than CABG and valve or aortic\n* Concurrent participation in other clinical trials.\n* Previous use of any probiotics, prebiotics, adsorbent dietary supplements, Vitamin C and\u002For Omega 3 fatty acids.","ALL","80 Years",{"count":75,"type":22},108,[25],"Cardiovascular disease (CVD) remains the leading cause of death worldwide. Prevention of CAD by targeting modifiable factors remains a key public health priority. L-Ascorbic Acid (Vitamin C - Vit. C) and Omega 3 fatty acids, Eicosapentaenoic \u002F Docosahexaenoic Acid (EPO\u002FDHA), powerful but also necessary antioxidants for the human body, after observational studies as well as randomized studies seem to have a beneficial effect in the direction of the prevention of CVD with pleiotropic mechanisms. Lignin, a polymer of plant origin that is considered a dietary fiber, has a developed porous structure and can retain exogenous and endogenous toxins, and pathogenic microorganisms. Lactulose considered a prebiotic provides a selective substrate for the metabolism of saccharolytic bacteria with bifidogenic activity and multiple benefits to the host's gut health. Coronary artery bypass grafting (CABG) is an established surgical intervention and treatment of symptoms of myocardial ischemia that improves patient survival Optimal Medical Therapy (OMT) after coronary arterial bypass grafting (CABG) as described in current clinical practice could be made even better by the addition of these beneficial food supplements.\n\nA randomized controlled trial is proposed in an intervention group of 54 post-CABG patients who will be given daily orally in addition to the usual medication, 1000 mg Vitamin C, 840 mg EPO\u002FDHA, 2130 mg Lignin \\& 720 mg Lactulose and a control group of 54 patients (Control Group) in which only usual medication will be administered. The intervention will take place from the 15th postoperative day when CAGB patients are discharged and lasts for 2.5 months (10 weeks) postoperatively. The data will be collected on the 15th, 80-90th postop day in 6 months and 12 months postop and then the statistical analysis of the data will be performed. Considering the number of CABG surgeries performed electively in our clinic, this study is expected to be completed in approximately 2-3 years from the day of initiation.\n\nThe expected knowledge through the expected results such as these will emerge from this study is the potentially beneficial effect of our food supplements administration (intervention), i.e. Vitamin C, EPO\u002FDHA, Lignin \\& Lactulose, on the postoperative course of our patients. Some degree of improvement in the well-being and clinical picture of our patients postoperatively is expected, which will be thoroughly investigated in each phase of the study.",[79,80,81,82,83,51,84,85,86,87,88,89,90,30],"Cardio-pulmonary Bypass","Cardiovascular Diseases","Omega-3 Polyunsaturated Fatty Acids","Omega-3 Supplementation","Vitamin C","Postoperative Depression","Antioxidants","Lactulose","Postoperative","Optimal Medical Therapy","CABG","Coronary Artery Bypass Grafting",[79,80,92,83,85,86,93,51,94,88,89,90,95,96,97,98],"Omega-3 polyunsaturated fatty acids","Omega-3 supplementation","postoperative","postoperative depression","Lignin","adsorbent","prebiotics","NOT_YET_RECRUITING","2026-05-09",{"date":102,"type":56},"2026-05-13",{"date":104,"type":22},"2026-09-01",{"date":106,"type":22},"2028-12-01",{"name":108,"class":63},"Nicosia General Hospital",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":72,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":64},"100502342","phase-2-synbiotics-and-fecal-microbiota-transplantation-to-treat-non-alcoholic-steatohepatitis-100502342","NCT05821010","Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis","SYNCH","Inclusion Criteria:\n\n* biopsy-proven NASH obtained up to 32 weeks before screening: SAF Steatosis score ≥1, Activity ≥2, Fibrosis \\\u003C4; 50% of participants should at least have NASH fibrosis stage 1, 2 or 3 according to the NASH CRN fibrosis staging system based on tandem reading of two expert liver pathologists\n* fluency in Dutch or English\n* participants should be able to understand the information and give informed consent\n\nExclusion Criteria:\n\n* Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year before screening (significant alcohol consumption is defined as more than 2 international units\u002Fday for females and more than 3 international units\u002Fday for males, on average; 1 international unit contains ±14 grams of alcohol)\n* liver cirrhosis or hepatocellular carcinoma\n* hepatitis B and\u002For C\n* auto-immune hepatitis\n* Wilson's disease\n* primary sclerosing cholangitis\n* primary biliary cholangitis\n* alpha-1-antitripsine deficiency and hemochromatosis\n* history of liver transplant, current placement on a liver transplant list\n* use of pre-, pro- or synbiotics\n* use of systemic antibiotics 3 month prior to randomization\n* use of tamoxifen, methotrexate or amiodarone\n* prior or planned bariatric surgery\n* active GLP-1 receptor agonist treated diabetes mellitus\n* bleeding disorder\n* International normalized ratio (INR) of prothrombin time \\>1.4 or platelet count \\\u003C100 109\u002FL at screening\n* anti-platelet\u002Fcoagulant therapy use which cannot be temporarily discontinued\n* any major cardiovascular event within 6 months prior to screening (e.g. myocardial infarction, cerebrovascular accident)\n* prolonged compromised immunity (e.g. recent cytotoxic chemotherapy, HIV-infection with a CD4 count \\\u003C 240)\n* active or prior history of invasive malignancy (except for curatively treated in situ carcinomas \\[e.g., cervix\\] or non-melanoma skin cancer) unless a complete remission was achieved\n* surgery scheduled for the trial duration period, except for minor surgical procedures, in the opinion of the investigator\n* pregnant or nursing women\n* any condition which, in the investigator's opinion, might jeopardize participants' safety or compliance with the protocol\n* participation in another concomitant clinical trial.","18 Years","75 Years",{"count":119,"type":22},48,[121],"PHASE2","The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation capsules to reduce NASH in patients with fibrotic NASH. The main questions to answer are:\n\n1. Can NASH be treated by altering the gut microbiota using LFMT capsules?\n2. Can NASH be treated using a syntrophic cocktail of synbiotics and will these strains strengthen the effect of FMT?\n3. What are the underlying mechanism by which the aforementioned treatments attenuate NASH?\n\nParticipants will be treated with FMT-capsules or placebo, and all participants will receive a cocktail of 3 strains of probiotics and one type of prebiotic.",[124,125,126,127,30,128,129,130,131],"Non Alcoholic Steatohepatitis","Non-Alcoholic Fatty Liver Disease","Fecal Microbiota Transplantation","FMT","Probiotics","Microbiome","Intestinal Microbiome","Gut Microbiome","2024-08-26",{"date":134,"type":56},"2024-08-27",{"date":136,"type":56},"2023-03-17",{"date":138,"type":22},"2026-08-20",{"name":140,"class":63},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]